Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab Alone or With Chemotherapy in PD-L1 ≥ 50% NSCLC
NCT07274384Phase 2Not yet recruiting
- Sponsor
- Vita-Salute San Raffaele University
- Start
- Jan 2026
- Primary completion
- Dec 2029
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
01
Overview
A Phase 2 trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Vita-Salute San Raffaele University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07274384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07274384.